Skip to main content

New safety warning for medicines used in arthritis and other inflammatory conditions

Safety advisory

A safety warning has been added to a class of medicines called Janus Kinase inhibitors used for chronic inflammatory conditions. This is based on a clinical trial of one of the medicines in this class called tofacitinib which found an increased risk of serious side effects in some groups of people.



Help us improve the Therapeutic Goods Administration site